The FDA on January 16, 2025, granted traditional approval to CALQUENCE® (Acalabrutinib) with Bendamustine and Rituximab for adults with previously untreated Mantle Cell Lymphoma (MCL) who are ineligible for autologous Hematopoietic Stem Cell Transplantation (HSCT). CALQUENCE® is a product of AstraZeneca.
Bottom Ad
Advertisement
Subscribe
